Call 1-844-EMPLICITI (1-844-367-5424)

This site is intended for U.S. Healthcare Professionals only.

Visit the EMPLICITI Patient Site

Bristol-Myers Squibb Resources | BMS Access Support®

Call 1-844-EMPLICITI(1-844-367-5424)

Visit the EMPLICITI Patient Site

This site is intended for
U.S. Healthcare Professionals only.

BMS Access Support®

Bristol-Myers Squibb Resources

U.S. Full Prescribing
Information

Patient Information

 

 

Call 1-844-EMPLICITI (1-844-367-5424)

Visit the EMPLICITI Patient Site

This site is intended for
U.S. Healthcare Professionals only.

BMS Access Support®

Bristol-Myers Squibb Resources

U.S. Full Prescribing
Information

Patient Information

INDICATIONS

EMPLICITI® (elotuzumab) is indicated for the treatment of adult patients with multiple myeloma in combination with:

  • lenalidomide and dexamethasone after one to three prior therapies
  • pomalidomide and dexamethasone after at least two prior therapies including lenalidomide and a proteasome inhibitor
Close

For your appropriate patients with relapsed
or refractory multiple myeloma

EMPOWER

THE JOURNEY

Primary analysis of PFS conducted with a minimum follow-up of 9.1 months:
HR 0.54; 95% CI: 0.34, 0.86; P=0.0078 (primary endpoint)1*

EMPLICITI + Pd: DOUBLE THE EFFICACY vs Pd ALONE1

DOUBLE THE mPFS (PRIMARY ENDPOINT)

EPd
10.25
MONTHS
Pd
4.67
MONTHS
(EPd, 95% CI: 5.59, NE; Pd, 95% CI: 2.83, 7.16)

DOUBLE THE ORR (SECONDARY ENDPOINT)

EPd
53.3%
Pd
26.3%
(EPd, 95% CI: 40.0, 66.3; Pd, 95% CI: 15.5, 39.7;
P=0.0029)

 

*

A Phase 2, randomized, open-label clinical study of EMPLICITI with pomalidomide and dexamethasone (EPd) vs Pd alone in patients with multiple myeloma (EPd, n=60; Pd, n=57). Patients must have received at least 2 prior lines of therapy, including lenalidomide and a proteasome inhibitor, and be refractory to the most recent therapy. Primary endpoint: PFS. Secondary endpoints: ORR and OS.1,2

 

SELECTED IMPORTANT SAFETY
INFORMATION

EMPLICITI® (elotuzumab) with pomalidomide and dexamethasone is associated with Warnings and Precautions related to:
Infusion Reactions, Infections, Second Primary Malignancies, Hepatotoxicity, Interference with Determination of Complete Response, Pregnancy/Females and Males of Reproductive Potential, and Adverse Reactions.

Please see detailed Important Safety Information below.

CI, confidence interval; HR, hazard ratio; NE, not estimable; ORR, overall response rate; OS, overall survival; Pd, pomalidomide + dexamethasone; PFS, progression-free survival.

 
 
More Important Safety Information

Important Safety Information More Important Safety InformationCollapse

Important Safety Information

Infusion Reactions

  • Infusion reactions were reported in 10% of patients treated with EMPLICITI in the ELOQUENT-2 trial [EMPLICITI + lenalidomide + dexamethasone (ERd) vs lenalidomide + dexamethasone (Rd)] and 3.3% in the ELOQUENT-3 trial [EMPLICITI + pomalidomide + dexamethasone (EPd) vs pomalidomide + dexamethasone (Pd)].
  • In the ELOQUENT-2 trial, all infusion reactions were Grade 3 or lower, with Grade 3 infusion reactions occurring in 1% of patients. The most common symptoms included fever, chills, and hypertension. Bradycardia and hypotension also developed during infusions. In the trial, 5% of patients required interruption of the administration of EMPLICITI for a median of 25 minutes due to infusion reactions, and 1% of patients discontinued due to infusion reactions. Of the patients who experienced an infusion reaction, 70% (23/33) had them during the first dose.
  • In the ELOQUENT-3 trial, the only infusion reaction symptom was chest discomfort (2%), which was Grade 1. All the patients who experienced an infusion reaction had them during the first treatment cycle.
  • If a Grade 2 or higher infusion reaction occurs, interrupt the EMPLICITI infusion and institute appropriate medical and supportive measures. If the infusion reaction recurs, stop the EMPLICITI infusion and do not restart it on that day. Severe infusion reactions may require permanent discontinuation of EMPLICITI therapy and emergency treatment.
  • Premedicate with dexamethasone, H1 blocker, H2 blocker, and acetaminophen prior to EMPLICITI infusion.

Infections

  • In the ELOQUENT-2 trial (N=635), infections were reported in 81% of patients in the ERd arm and 74% in the Rd arm. Grade 3-4 infections were 28% (ERd) and 24% (Rd). Discontinuations due to infections were 3.5% (ERd) and 4.1% (Rd). Fatal infections were 2.5% (ERd) and 2.2% (Rd). Opportunistic infections were reported in 22% (ERd) and 13% (Rd). Fungal infections were 10% (ERd) and 5% (Rd). Herpes zoster was 14% (ERd) and 7% (Rd).
  • In the ELOQUENT-3 trial (N=115), infections were reported in 65% of patients in both the EPd arm and the Pd arm. Grade 3-4 infections were reported in 13% (EPd) and 22% (Pd). Discontinuations due to infections were 7% (EPd) and 5% (Pd). Fatal infections were 5% (EPd) and 3.6% (Pd). Opportunistic infections were reported in 10% (EPd) and 9% (Pd). Herpes zoster was reported in 5% (EPd) and 1.8% (Pd).
  • Monitor patients for development of infections and treat promptly.

Second Primary Malignancies

  • In the ELOQUENT-2 trial (N=635), invasive second primary malignancies (SPM) were 9% (ERd) and 6% (Rd). The rate of hematologic malignancies was the same between ERd and Rd treatment arms (1.6%). Solid tumors were reported in 3.5% (ERd) and 2.2% (Rd). Skin cancer was reported in 4.4% (ERd) and 2.8% (Rd).
  • In the ELOQUENT-3 trial (N=115), invasive SPMs were 0% (EPd) and 1.8% (Pd).
  • Monitor patients for the development of SPMs.

Hepatotoxicity

  • In the ELOQUENT-2 trial (N=635), AST/ALT >3X the upper limit, total bilirubin >2X the upper limit, and alkaline phosphatase <2X the upper limit were 2.5% (ERd) vs 0.6% (Rd). Of 8 patients experiencing hepatotoxicity, 2 patients discontinued treatment while 6 patients had resolution and continued. Monitor liver enzymes periodically. Stop EMPLICITI upon ≥Grade 3 elevation of liver enzymes. Continuation of treatment may be considered after return to baseline values.

Interference with Determination of Complete Response

  • EMPLICITI is a humanized IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis and immunofixation assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and possibly relapse from complete response in patients with IgG kappa myeloma protein.

Pregnancy/Females and Males of Reproductive Potential

  • There are no available data on EMPLICITI use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.
  • There is a risk of fetal harm, including severe life-threatening human birth defects, associated with lenalidomide and pomalidomide, and they are contraindicated for use in pregnancy. Refer to the respective product full prescribing information for requirements regarding contraception and the prohibitions against blood and/or sperm donation due to presence and transmission in blood and/or semen and for additional information.

Adverse Reactions

  • ELOQUENT-2 trial:
    • Serious adverse reactions were 65% (ERd) and 57% (Rd). The most frequent serious adverse reactions in the ERd arm compared to the Rd arm were: pneumonia (15%, 11%), pyrexia (7%, 5%), respiratory tract infection (3.1%, 1.3%), anemia (2.8%, 1.9%), pulmonary embolism (3.1%, 2.5%), and acute renal failure (2.5%, 1.9%).
    • The most common adverse reactions in ERd and Rd, respectively (≥20%) were fatigue (62%, 52%), diarrhea (47%, 36%), pyrexia (37%, 25%), constipation (36%, 27%), cough (34%, 19%), peripheral neuropathy (27%, 21%), nasopharyngitis (25%, 19%), upper respiratory tract infection (23%, 17%), decreased appetite (21%, 13%), and pneumonia (20%, 14%).
  • ELOQUENT-3 trial:
    • Serious adverse reactions were 22% (EPd) and 15% (Pd). The most frequent serious adverse reactions in the EPd arm compared to the Pd arm were: pneumonia (13%, 11%) and respiratory tract infection (7%, 3.6%).
    • The most common adverse reactions in EPd arm (≥20% EPd) and Pd, respectively, were constipation (22%, 11%) and hyperglycemia (20%, 15%).

Please see the Full Prescribing Information.

References

  1. EMPLICITI [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811-1822.
  3. Lonial S, Dimopoulos M, Weisel K, et al. Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). Poster presentation at: 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1-5, 2018; Chicago, IL. Poster #8040.
  4. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621-631.
  5. BMS-REF-ELOT 039 [Data on file]. Bristol-Myers Squibb. 2016.
  6. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(protocol):1-175.
  7. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(suppl):1-18.
  8. BMS-REF-ELOT 047 [Data on file]. Bristol-Myers Squibb. 2016.
  9. Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018;17(7):1454-1463.
  10. Dimopoulos MA, Weisel K, Lonial S, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial. Presented at: 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA. Oral presentation OAB-021.
689US1803827-02-01 01/20

Legal Notice | Privacy Policy
Site Map | Contact Us

EMPLICITI, the related logo, and Access Support are registered trademarks of Bristol-Myers Squibb Company. All other trademarks are property of their respective owners.

© 2018 Bristol-Myers Squibb Company. All rights reserved.

689US1803827-01-01 12/18

Please verify that you are a U.S. Healthcare Professional.

This site is intended for U.S. Healthcare Professionals.

I am a U.S. Healthcare Professional

YES

I am not a U.S. Healthcare Professional

RETURN

You are about to leave this Bristol-Myers Squibb Company site. You are being redirected to another Bristol-Myers Squibb Company site.

Would you like to leave this site?

YES

NO

You are now leaving this Bristol-Myers Squibb site.

This Internet site may provide links or references to other sites.BMS has no responsibility for the content of such other sites andis not liable for any damages or injury arising from that content.Any links to other sites are provided merely as a convenience tothe users of this Internet site.

PROCEED

CANCEL

 

BMS is committed to providing continued access to medicines for the patients who depend on us. For any questions about BMS medicines during this time,
please contact 1-800-721-8909.

CONTINUE TO SITE

©2020 Bristol-Myers Squibb Company

All Rights Reserved. NOUS2001187-01  04/20

This website is best viewed using the vertical display on your mobile device.

This website is best viewed using the horizontal display on your tablet device.